Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.
Aside from vaccines, the advent of several effective COVID-19 antiviral therapies, including Pfizer’s Paxlovid, provides hope for ending the pandemic. Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
The chairman of the Gavi vaccine alliance, Jose Manuel Barroso, said on January 19 that an additional $5.2 billion is needed to continue to deliver vaccines at scale.
The United States had administered 401,819,240 doses of Covid-19 vaccines in the country as of the morning of Oct. 9 and distributed 487,277,035 doses, the U.S. Centers for Disease Control and Prevention said.
The number of new Covid-19 infections dropped during the past month throughout the Americas, even though only 37 percent of the people in Latin America and the Caribbean are fully vaccinated, the Pan American Health Organization (PAHO) said on Oct. 6.
A World Health Organization (WHO) panel on Sept. 24 recommended the use of Regeneron and Roche’s Covid-19 antibody cocktail for patients at high risk of hospitalizations and those severely ill with no natural antibodies.
The United States plans to donate an additional 500 million Covid-19 vaccines made by Pfizer Inc. and BioNTech SE to nations around the world, lifting the total the country is sharing to more than 1 billion doses, according to a source familiar with the plans.
The U.S. Food and Drug Administration said on Sept. 16 it has revised the FDA’s emergency use authorization for Eli Lilly’s Covid-19 antibody cocktail to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease.
U.S. President Joe Biden will announce new steps to slow the spread of Covid-19 before the U.N. General Assembly meets, Surgeon General Dr. Vivek Murthy said Sept. 12.
Vaccine developer Novavax Inc. said on Sept. 10 at least 2 billion doses of the company’s Covid-19 vaccine would be available in 2022.